Figure S7 from Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and is Required for Checkpoint Blockade Tumor Immunotherapy

Lüjun Chen,Runzi Sun,Jing Xu,Wensi Zhai,Dachuan Zhang,Min Yang,Cuihua Yue,Yichao Chen,Song Li,Hēth Turnquist,Jingting Jiang,Binfeng Lu

DOI: https://doi.org/10.1158/2326-6066.22543717.v1

2023-01-01

Abstract:Flow analysis of DC population in B16 and MC38 tumor models.

What problem does this paper attempt to address?

Figure S5 from Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and is Required for Checkpoint Blockade Tumor Immunotherapy

Lujun Chen,Runzi Sun,Junchi Xu,Wensi Zhai,Dachuan Zhang,Min Yang,Cuihua Yue,Yichao Chen,Song Li,Heth Turnquist,Jingting Jiang,Binfeng Lu

DOI: https://doi.org/10.1158/2326-6066.22543723.v1

2023-01-01

Abstract:Overexpression of secreted IL-33 in B16 tumors increased effector function of the tumor infiltrating T cells.
Figure S6 from Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy

Lüjun Chen,Runzi Sun,Jing Xu,Wensi Zhai,Dachuan Zhang,Min Yang,Cuihua Yue,Yichao Chen,Song Li,Hēth Turnquist,Jingting Jiang,Binfeng Lu

DOI: https://doi.org/10.1158/2326-6066.22543720

2023-01-01

Abstract:Dependence of CD8+ T cell function on ST2 and CD103.
Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy.

Lujun Chen,Runzi Sun,Junchi Xu,Wensi Zhai,Dachuan Zhang,Min Yang,Cuihua Yue,Yichao Chen,Song Li,Heth Turnquist,Jingting Jiang,Binfeng Lu

DOI: https://doi.org/10.1158/2326-6066.CIR-19-1024

IF: 10.1

2020-01-01

Cancer Immunology Research

Abstract:Immune checkpoint blockade (ICB) immunotherapy has revolutionized cancer treatment by prolonging overall survival of patients with cancer. Despite advances in the clinical setting, the immune cellular network in the tumor microenvironment (TME) that mediates such therapy is not well understood. IL33 is highly expressed in normal epithelial cells but downregulated in tumor cells in advanced carcinoma. Here, we showed that IL33 was induced in tumor cells after treatment with ICB such as CTL antigen-4 (CTLA-4) and programmed death-1 (PD-1) mAbs. ST2 signaling in nontumor cells, particularly CD8+ T cells, was critical for the antitumor efficacy of ICB immunotherapy. We demonstrated that tumor-derived IL33 was crucial for the antitumor efficacy of checkpoint inhibitors. Mechanistically, IL33 increased the accumulation and effector function of tumor-resident CD103+CD8+ T cells, and CD103 expression on CD8+ T cells was required for the antitumor efficacy of IL33. In addition, IL33 also increased the numbers of CD103+ dendritic cells (DC) in the TME and CD103+ DC were required for the antitumor effect of IL33 and accumulation of tumor-infiltrating CD8+ T cells. Combination of IL33 with CTLA-4 and PD-1 ICB further prolonged survival of tumor-bearing mice. Our study established that the "danger signal" IL33 was crucial for mediating ICB cancer therapy by promoting tumor-resident adaptive immune responses.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Peng Xiao,Xiaopeng Wan,Bijun Cui,Yang Liu,Chenyang Qiu,Jiabing Rong,Mingzhu Zheng,Yinjing Song,Luoquan Chen,Jia He,Qinchun Tan,Xiaojia Wang,Xiying Shao,Yuhua Liu,Xuetao Cao,Qingqing Wang

DOI: https://doi.org/10.1080/2162402x.2015.1063772

2015-01-01

OncoImmunology

Abstract:Tumor-induced, myeloid-derived suppressor cells (MDSCs)-mediated immune dysfunction is an important mechanism that leads to tumor immune escape and the inefficacy of cancer immunotherapy. Importantly, tumor-infiltrating MDSCs have much stronger ability compared to MDSCs in the periphery. However, the mechanisms that tumor microenvironment induces the accumulation and function of MDSCs are poorly understood. Here, we report that Interleukin-33 (IL-33) - a cytokine which can be abundantly released in tumor tissues both in 4T1-bearing mice and breast cancer patients, is crucial for facilitating the expansion of MDSCs. IL-33 in tumor microenvironment reduces the apoptosis and sustains the survival of MDSCs through induction of autocrine secretion of GM-CSF, which forms a positive amplifying loop for MDSC accumulation. This is in conjunction with IL-33-driven induction of arginase-1 expression and activation of NF-kappa B and MAPK signaling in MDSCs which augments their immunosuppressive ability, and histone modifications were involved in IL-33 signaling in MDSCs. In ST2 (/) mice, the defect of IL-33 signaling in MDSCs attenuates the immunosuppressive and pro-tumoral capacity of MDSCs. Our results identify IL-33 as a critical mediator that contributes to the abnormal expansion and enhanced immunosuppressive function of MDSCs within tumor microenvironment, which can be potentially targeted to reverse MDSC-mediated tumor immune evasion.
Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402079

2023-01-01

Abstract:Identification of established CCDC134 transgenic mice.
Supplementary Figure 7 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384248

2023-01-01

Abstract:Supplementary Figure 7 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 6 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384251

2023-01-01

Abstract:Supplementary Figure 6 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384260.v1

2023-01-01

Abstract:Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Differential Requirements for CD4+ T Cells in the Efficacy of the Anti-Pd-1+lag-3 and Anti-Pd-1+ctla-4 Combinations in Melanoma Flank and Brain Metastasis Models.

Manali S. Phadke,Jiannong Li,Zhihua Chen,Paulo C. Rodriguez,Jessica K. Mandula,Lilit Karapetyan,Peter A. Forsyth,Y. Ann Chen,Keiran S. M. Smalley

DOI: https://doi.org/10.1136/jitc-2023-007239

IF: 12.469

2023-01-01

Journal for ImmunoTherapy of Cancer

Abstract:BackgroundAlthough the anti-PD-1+LAG-3 and the anti-PD-1+CTLA-4 combinations are effective in advanced melanoma, it remains unclear whether their mechanisms of action overlap.MethodsWe used single cell (sc) RNA-seq, flow cytometry and IHC analysis of responding SM1, D4M-UV2 and B16 melanoma flank tumors and SM1 brain metastases to explore the mechanism of action of the anti-PD-1+LAG-3 and the anti-PD-1+CTLA-4 combination. CD4+ and CD8+ T cell depletion, tetramer binding assays and ELISPOT assays were used to demonstrate the unique role of CD4+T cell help in the antitumor effects of the anti-PD-1+LAG-3 combination.ResultsThe anti-PD-1+CTLA-4 combination was associated with the infiltration of FOXP3+regulatory CD4+ cells (Tregs), fewer activated CD4+T cells and the accumulation of a subset of IFN gamma secreting cytotoxic CD8+T cells, whereas the anti-PD-1+LAG-3 combination led to the accumulation of CD4+T helper cells that expressed CXCR4, TNFSF8, IL21R and a subset of CD8+T cells with reduced expression of cytotoxic markers. T cell depletion studies showed a requirement for CD4+T cells for the anti-PD-1+LAG-3 combination, but not the PD-1-CTLA-4 combination at both flank and brain tumor sites. In anti-PD-1+LAG-3 treated tumors, CD4+T cell depletion was associated with fewer activated (CD69+) CD8+T cells and impaired IFN gamma release but, conversely, increased numbers of activated CD8+T cells and IFN gamma release in anti-PD-1+CTLA-4 treated tumors.ConclusionsTogether these studies suggest that these two clinically relevant immune checkpoint inhibitor (ICI) combinations have differential effects on CD4+T cell polarization, which in turn, impacted cytotoxic CD8+T cell function. Further insights into the mechanisms of action/resistance of these clinically-relevant ICI combinations will allow therapy to be further personalized.
Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384254

2023-01-01

Abstract:Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384263

2023-01-01

Abstract:Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142126

2024-01-01

Abstract:Supplementary Figure S6. Treg tumor infiltration after local RT in MC38 tumors and splenic cDC isolation strategy.
Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384257

2023-01-01

Abstract:Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure S1 from B7 Blockade Alters the Balance Between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of Cancer

Penghui Zhou,Xincheng Zheng,Huiming Zhang,Yang Liu,Pan Zheng

DOI: https://doi.org/10.1158/1078-0432.22440672.v1

2023-01-01

Abstract:Supplementary Figure S1 from B7 Blockade Alters the Balance between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of Cancer
Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402073

2023-01-01

Abstract:Involvement of CD4+ T cells in the induction of antitumor activity by CCDC134.
Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384266

2023-01-01

Abstract:Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
IL-33 Drives the Antitumor Effects of Dendritic Cells Via the Induction of Tc9 Cells

Ning Liu,Yuxue Jiang,Jintong Chen,He Nan,Yinghua Zhao,Xiao Chu,Alison Wang,Dongjiao Wang,Tianxue Qin,Sujun Gao,Qing Yi,Ying Yue,Siqing Wang

DOI: https://doi.org/10.1038/s41423-018-0166-0

2018-01-01

Abstract:Dendritic cell (DC) tumor vaccines exert their antitumor effects through the induction of effector T cells. We recently identified Tc9 cells as a new potent antitumor effector T cell subset. However, approaches to direct DCs to preferably prime antitumor Tc9 cells should be further exploited. Here, we demonstrate that the addition of interleukin (IL)-33 potently promotes the induction of Tc9 cells by DCs in vitro and in vivo. IL-33 treatment also drives the cytotoxic activities of DC-induced Tc9 cells. Notably, IL-33 treatment enhances cell survival and proliferation of DC-primed CD8 + T cells. More importantly, the addition of IL-33 during in vitro priming of tumor-specific Tc9 cells by DCs increases the antitumor capability of Tc9 cells. Mechanistic studies demonstrated that IL-33 treatment inhibits exhaustive CD8 + T cell differentiation by inhibiting PD-1 and 2B4 expression and increasing IL-2 and CD127 (IL-7 receptor-α, IL-7Rα) expression in CD8 + T cells. Finally, the addition of IL-33 further promotes the therapeutic efficacy of DC-based tumor vaccines in the OT-I mouse model. Our study demonstrates the important role of IL-33 in DC-induced Tc9 cell differentiation and antitumor immunity and may have important clinical implications.
Critical Role of Dendritic Cell-Derived Il-27 in Antitumor Immunity Through Regulating the Recruitment and Activation of Nk and Nkt Cells

Jun Wei,Siyuan Xia,Huayan Sun,Song Zhang,Jingya Wang,Huiyuan Zhao,Xiaoli Wu,Xi Chen,Jianlei Hao,Xinglong Zhou,Zhengmao Zhu,Xiang Gao,Jian-xin Gao,Puyue Wang,Zhenzhou Wu,Liqing Zhao,Zhinan Yin

DOI: https://doi.org/10.4049/jimmunol.1300328

2013-01-01

The Journal of Immunology

Abstract:Critical roles of IL-27 in autoimmune diseases and infections have been reported; however, the contribution of endogenous IL-27 to tumor progression remains elusive. In this study, by using IL-27p28 conditional knockout mice, we demonstrate that IL-27 is critical in protective immune response against methyl-cholanthrene-induced fibrosarcoma and transplanted B16 melanoma, and dendritic cells (DCs) are the primary source. DC-derived IL-27 is required for shaping tumor microenvironment by inducing CXCL-10 expression in myeloid-derived suppressor cells and regulating IL-12 production from DCs, which lead to the recruitment and activation of NK and NKT cells resulting in immunological control of tumors. Indeed, reconstitution of IL-27 or CXCL-10 in tumor site significantly inhibits tumor growth and restores the number and activation of NK and NKT cells. In summary, our study identifies a previous unknown critical role of DC-derived IL-27 in NK and NKT cell-dependent antitumor immunity through shaping tumor microenvironment, and sheds light on developing novel therapeutic approaches based on IL-27.
Supplementary Figure S5 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.22399028

2023-01-01

Abstract:Supplementary Figure S5 PDF file - 145K, A . Recruitment of CD8+CD11c+ and CD11b+F4/80+ cells to the tumor sites following Ad.Flagrp170 therapy. B16 tumor-bearing mice were treated with indicated adenoviruses, and cell infiltration was analyzed using FACS by gating on tumor infiltrating leukocytes. B. IL-12p70 production in tumor-infiltrating myeloid cells was measured using intracellular cytokine staining assays. CD11c+ cells are not the major source of IL-12 (n=3, representative of 3 independent experiments). C. Flow cytometry analysis of splenic CD11c+ cells in DTx (8 ng/kg)-treated chimera mice reconstituted with BM from DTRtg mice

Figure S7 from Tumor-Derived IL33 Promotes Tissue-Resident CD8<sup>+</sup> T Cells and is Required for Checkpoint Blockade Tumor Immunotherapy

Figure S5 from Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and is Required for Checkpoint Blockade Tumor Immunotherapy

Figure S6 from Tumor-Derived IL33 Promotes Tissue-Resident CD8<sup>+</sup> T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy

Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy.

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure 7 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 6 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Differential Requirements for CD4+ T Cells in the Efficacy of the Anti-Pd-1+lag-3 and Anti-Pd-1+ctla-4 Combinations in Melanoma Flank and Brain Metastasis Models.

Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure S1 from B7 Blockade Alters the Balance Between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of Cancer

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

IL-33 Drives the Antitumor Effects of Dendritic Cells Via the Induction of Tc9 Cells

Critical Role of Dendritic Cell-Derived Il-27 in Antitumor Immunity Through Regulating the Recruitment and Activation of Nk and Nkt Cells

Supplementary Figure S5 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Figure S7 from Tumor-Derived IL33 Promotes Tissue-Resident CD8&lt;sup&gt;+&lt;/sup&gt; T Cells and is Required for Checkpoint Blockade Tumor Immunotherapy